:: Library Catalog

Cover Image

Saved in:

Bibliographic Details
Main Authors:	Guofu Mao, Haizhen Lan
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	https://onlinelibrary.wiley.com/doi/10.1111/apt.70710
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: Shingles Risk in IBD —More Evidence to Support Routine Preventive Vaccination?
by: Keith Bodger
Published: (2025)

Overall and Comparative Risk of Shingles With Advanced Therapies in Patients With Inflammatory Bowel Diseases
by: Dhruv Ahuja, et al.
Published: (2025)

Letter: The Hidden Truth of IBD Risk—From Antibiotics to Environmental Factors
by: Xueneng Yang, et al.
Published: (2025)

Letter: Diet to Modify Risk of IBD—More Plants and Less Processed Food?
by: Alice S. Day, et al.
Published: (2025)

Letter: Unlocking the Full Potential of Dietary Therapy in IBD —The Case for Universal Eating Disorder Screening
by: Luisa Bertin, et al.
Published: (2026)

Editorial: Inflammation and Not Glucocorticoid Therapy is the Key Driver of Fracture Risk in IBD
by: Darcy Quinn Holt, et al.
Published: (2024)

Letter: Addressing opioid exposure and associated harms in patients with IBD
by: Christian P. Selinger, et al.
Published: (2024)

Letter: Differences in Disease Characteristics and Treatment Exposures Between Paediatric and Adult‐Onset IBD
by: Xinli Chen, et al.
Published: (2024)

Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply
by: Chachrit Khunsriraksakul, et al.
Published: (2025)

Letter: Double‐Dose Hepatitis B Vaccination in IBD —A Step Forward in Protecting Immunosuppressed Patients
by: Luisa Bertin, et al.
Published: (2026)

Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply
by: Arta Aliu, et al.
Published: (2024)

Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management
by: Jakob B. Seidelin
Published: (2024)

The Effectiveness of Medical Therapies for Joint, Skin and Eye Extraintestinal Manifestations in IBD—An Umbrella Review
by: Olga M. Nardone, et al.
Published: (2025)

Editorial: Advanced glycation end products ‐ a dietary culprit for IBD in the genetically susceptible?
by: Fahim Ebrahimi, et al.
Published: (2024)

Editorial: Disentangling Early‐Life Antibiotics and Infections as Risk Factors for the Development of Childhood IBD
by: Katherine L. Stone, et al.
Published: (2024)

Letter: Putting Crohn's Risk Prediction to Work in Perianal Fistula—Calibration, Thresholds, and Transport
by: Emmanuel Pio Pastore
Published: (2025)

Editorial: Getting to the Heart of the Matter in IBD
by: Ashwin N. Ananthakrishnan
Published: (2025)

Editorial: Getting to the Heart of the Matter in IBD—Authors' Reply
by: Ramin Ebrahimi, et al.
Published: (2025)

Editorial: Targeting Urgency in IBD —A Historical Divide
by: Daniele Noviello, et al.
Published: (2025)

Letter: Supporting the Role of Enzyme Therapy in Management of Coeliac Disease
by: Finlay Macrae
Published: (2025)

Editorial: Updated COVID‐19 Boosters—Tailoring Protection for Patients With IBD
by: James L. Alexander, et al.
Published: (2024)

Editorial: Targeting Urgency in IBD —A Historical Divide. Authors' Reply
by: Parul Tandon, et al.
Published: (2025)

Treatment‐Free Outcomes Following Surgery for IBD : A Nationwide Cohort Study
by: Adam S. Faye, et al.
Published: (2025)

Review Article: Green Management of IBD—New Paradigms for an Eco‐Friendly Approach
by: Giovanni Cammarota, et al.
Published: (2024)

Faecal biomarkers for diagnosis and prediction of disease course in treatment‐naïve patients with IBD
by: Maria Ling Lundström, et al.
Published: (2024)

Editorial: Toward Safer Pain Management in IBD—Lessons From Prescription Patterns
by: Shabari Shenoy, et al.
Published: (2025)

Editorial: PSC as an Independent Risk Factor for CRC Without IBD : Can Observed Epidemiological Trends Help Uncover Biological Mechanisms and Guide Surveillance Strategies?
by: Natassia Tan, et al.
Published: (2025)

Letter: Risks of proton pump inhibitor treatment in cirrhotic patients
by: Jiamei Wang, et al.
Published: (2024)

Letter: Steroid Tapering in Ulcerative Colitis: The Importance of Disease Severity and Maintenance Therapy
by: Rónán O'Connor, et al.
Published: (2026)

Letter: Is Routine ECG Monitoring Redundant During Terlipressin Therapy in HRS ‐ AKI ?
by: Xing Wang
Published: (2025)

Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence
by: Manjeet Kumar Goyal, et al.
Published: (2026)

Letter: Unmasking the Risks—The Need for Robust Data on Baclofen in Cirrhotic Patients
by: Zainab Salman
Published: (2026)

Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate
by: Wen‐Juei Jeng, et al.
Published: (2025)

Letter: Combination Therapies With Vitamin E for Metabolic Dysfunction‐Associated Steatotic Liver Disease
by: Stergios A. Polyzos, et al.
Published: (2024)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
by: Zhidong Zhou, et al.
Published: (2025)

Editorial: Toward Safer Pain Management in IBD—Lessons From Prescription Patterns. Authors' Reply
by: Samantha Baillie, et al.
Published: (2025)

Letter: Gas‐Sensing Capsules Advance Colonic Physiology Research Toward Clinical Translation
by: Anastasios Koulaouzidis, et al.
Published: (2025)

Editorial: Redefining Safety in Post‐Liver Transplant IBD —Why Therapeutic Effectiveness Is the Ultimate Shield. Authors' Reply
by: Simone Chin, et al.
Published: (2025)

Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate—Authors' Reply
by: Ying‐Nan Tsai, et al.
Published: (2025)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR
by: Zhejin Shi, et al.
Published: (2026)